Data References
[1] LiverTox; Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD)
National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Fluoroquinolones. [Updated 2020 Mar 10]
[2] Takahashi H, Hayakawa I, Akimoto T. [The history of the development and changes of quinolone antibacterial agents]
Yakushigaku Zasshi. 2003;38(2):161-79. Japanese. PMID: 15143768.
[3] Center for Drug Evaluation and Research, F. (2018, December 20).
FDA warns about increased risk of ruptures or tears in the aorta blood. U.S. Food and Drug Administration.
[4] FDA. (2016, May 12)
FDA advises restricting use of fluoroquinolones for certain infections. U.S. Food and Drug Administration.
[5] FDA. (2018, July 18)
FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. U.S. Food and Drug Administration.
[6] Hall, M. M., Finnoff, J. T., & Smith, J. (2011, February 17)
Musculoskeletal complications of fluoroquinolones: Guidelines and precautions for usage in the athletic population. Science Direct - PM&R.
[7] FDA (2017)
Fluoroquinolone safety labeling changes - U.S. Food and Drug Administration, FDA/DER Drug Information Webinar.
[11] Michalak, K., Sobolewska-Włodarczyk, A., Włodarczyk, M., Sobolewska, J., Woźniak, P., & Sobolewski, B. (2017, September 25)
“Treatment of the fluoroquinolone-associated disability: The pathobiochemical implications. Oxidative medicine and cellular longevity.”
[12] Rui Liu, Shiling Hu, Yongjing Zhang, Delu Che, Jiao Cao, Jue Wang, Tingting Zhao, Qianqian Jia, Nan Wang, Tao Zhang (2019, May)
“Mast cell-mediated hypersensitivity to fluoroquinolone is MRGPRX2 dependent.” Science Direct / International Immunopharmacology”
[14] Center for Drug Evaluation and Research, F. (2016, July 26)
FDA updates warnings for oral and injectable fluoroquinolone. U.S. Food and Drug Administration.
[19] OLIPHANT, PHARM.D., C. M., & GREEN, M.D., G. M. (2002, February 1)
Quinolones: A Comprehensive Overview. AAFP - Clinical Pharmacology.
[26] Pieper, S. (2021). Fluoroquinolone-Associated Disability (FQAD)
Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria. (1st ed). Springer.
[28] Sharma, D., Patel, R., Zaidi, S., Moklesur, M., Sarker, R., Lean, Q., Ming, L.
Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries. Front Pharmacol. 2017; 8: 546, published online 2017 Aug 21.
[30] Swallow, S. (2015)
9.5 Fluoroquinolone Antibiotics. Fluorine in Medical Chemistry | ScienceDirect Topics.
[31] Events
Open FDA Reporting, 2004-present Events.
[32] FDA (2023, December 7)
FDA Adverse Event Reporting System (FAERS) public dashboard. U.S. Food and Drug Administration.